濟民健康(603222.SH):控股子公司簽訂戰略合作框架協議
格隆匯5月29日丨濟民健康(603222.SH)公佈,為貫徹落實國家關於生物醫藥產業創新發展的戰略部署,充分發揮海南博鰲樂城國際醫療旅遊先行區(簡稱“樂城先行區”)“特許醫療、特許研究、特許國際交流”政策優勢,2025年5月28日,公司旗下博鰲國際醫院與達博生物本着“優勢互補、資源共享、協同創新、共拓全球”的合作原則,就加速新藥研發與臨牀轉化、構建“研發-臨牀-商業化”垂直整合模式,簽署了《戰略合作框架協議》。
細胞治療藥物研發是公司重點佈局和投入的方向之一,本協議的簽訂旨在發揮地方政策優勢,通過與外部合作,加強技術與人才互補,以臨牀需求驅動研發創新,拓展細胞與基因治療的管線佈局,打造“研發-臨牀-商業化”垂直整合模式,對公司的未來發展具有重要意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.